{"doi":"10.57603/ejt-272","title":"THE IMMENSE POTENTIAL OF XENOTRANSPLANTATION","abstract":"Surgeons working in the field of organ transplantation are increasingly directing attention to resolving the shortage of deceased human donor organs by the transplantation of organs from genetically-engineered pigs, a field known as xenotransplantation (cross-species transplantation). If the remaining immunologic hurdles can be overcome, the ready availability of pig organs would enable all suitable patients to receive an organ transplant. Furthermore, the organ graft would be available whenever needed, thus reducing the need for prolonged renal dialysis or other supportive therapies. In addition, with regard to protecting the graft from the human immune response, xenotransplantation provides us the first opportunity of modifying the donor rather than just suppressing the response in the recipient, which may have detrimental effects on the heath of the patient. However, xenotransplantation offers a much greater potential than just organ transplantation. Pig islets could prove to be a cure for diabetes mellitus, corneas for corneal blindness, and pig dopamine-producing cells may reduce the disabilities of Parkinson’s disease. Pig red blood cells offer the prospect of a limitless supply for transfusion, and the implantation of gene-edited pig heart valves may increase the viability of these valves far longer than at present. There would be unlimited skin and tissues for the treatment of burns and many other conditions. Importantly, living human donors would no longer be put at risk, and surgeons would no longer have to resort to the transplantation of organs of suboptimal status. Indeed, xenotransplantation could well be the next great medical revolution.","journal":"European Journal of Transplantation","year":2023,"id":392648,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9575,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":714395,"name":"Emanuele Cozzi","orcid":"0000-0001-7855-5055","position":1,"is_corresponding":false},{"id":681713,"name":"David K.C. Cooper","orcid":"0000-0003-4149-5452","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:18:56.730121Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}